{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:47:50Z","timestamp":1762980470564,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T00:00:00Z","timestamp":1513728000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1038\/s41391-017-0014-9","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T21:50:17Z","timestamp":1513806617000},"page":"306-318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation"],"prefix":"10.1038","volume":"21","author":[{"given":"Megan","family":"McNamara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-1754","authenticated-orcid":false,"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,20]]},"reference":[{"key":"14_CR1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/pcan.2016.30","volume":"19","author":"AB Weiner","year":"2016","unstructured":"Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004\u20132013). Prostate Cancer Prostatic Dis. 2016;19:395\u20137.","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"14_CR2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322.","journal-title":"N Engl J Med."},{"key":"14_CR3","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1056\/NEJMc1410239","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:1755\u20136.","journal-title":"N Engl J Med."},{"key":"14_CR4","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med."},{"key":"14_CR5","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS Bono de","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005.","journal-title":"N Engl J Med."},{"key":"14_CR6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138\u201348.","journal-title":"N Engl J Med."},{"key":"14_CR7","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med."},{"key":"14_CR8","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS Bono de","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147\u201354.","journal-title":"Lancet"},{"key":"14_CR9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med."},{"key":"14_CR10","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.juro.2015.06.106","volume":"194","author":"ED Crawford","year":"2015","unstructured":"Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015;194:1537\u201347.","journal-title":"J Urol."},{"key":"14_CR11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med."},{"key":"14_CR12","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163\u201377.","journal-title":"Lancet."},{"key":"14_CR13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377: 352\u2013360.","journal-title":"N Engl J Med."},{"key":"14_CR14","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377: 388\u2013351.","journal-title":"N Engl J Med."},{"key":"14_CR15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","volume":"70","author":"G Gravis","year":"2016","unstructured":"Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 Trial. Eur Urol. 2016;70:256\u201362.","journal-title":"Eur Urol."},{"key":"14_CR16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11864-016-0439-8","volume":"17","author":"DJ Stevens","year":"2016","unstructured":"Stevens DJ, Sooriakumaran P. Oligometastatic prostate cancer. Curr Treat Options Oncol. 2016;17:62.","journal-title":"Curr Treat Options Oncol."},{"key":"14_CR17","doi-asserted-by":"crossref","unstructured":"Sweeney CJ. Long term efficacy and QOL data of chemohormonal therapy in low and high volume hormone naive metastatic prostate cancer: E3805 CHAARTED trial. In: ESMO 2016 ABS 720PD. Milan Italy 2016.","DOI":"10.1093\/annonc\/mdw372.04"},{"key":"14_CR18","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","volume":"67","author":"ND James","year":"2015","unstructured":"James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with newly diagnosed metastatic prostate cancer in the \u201cdocetaxel era\u201d: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK\/06\/019). Eur Urol. 2015;67:1028\u201338.","journal-title":"Eur Urol."},{"key":"14_CR19","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","volume":"24","author":"M Hussain","year":"2006","unstructured":"Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984\u201390.","journal-title":"J Clin Oncol."},{"key":"14_CR20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0022-5347(05)64059-1","volume":"169","author":"TR Glass","year":"2003","unstructured":"Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003;169:164\u20139.","journal-title":"J Urol."},{"key":"14_CR21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","volume":"68","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol. 2015;68:325\u201334.","journal-title":"Eur Urol."},{"key":"14_CR22","doi-asserted-by":"crossref","unstructured":"Francini EGK, Xie W, Kantoff P, Harshman L, Tapllin ME, Sweeney C. Prior therapy and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based database (abs 221). In: Genitourinary Cancers Symposium. Orlando FL 2017.","DOI":"10.1200\/JCO.2017.35.6_suppl.221"},{"key":"14_CR23","doi-asserted-by":"crossref","unstructured":"Gravis GBJ, Chen YH, Liu G, Fizazi K, Carducci M, Ooudard S, Joly F, Jarrard D, Soulie M, Eisenberger M, Habibian M, Dreicer R, Garcia J, Hussain M, Kohli M, Vogelzang N, Picus J, DiPaola R, Sweeney C. Burden of metastatic hormone-sensitive prostate cancer to identify men more likely to benefit from early docetaxel. In: Genitourinary Cancers Symposium. Orlando FL 2017;Abs 136.","DOI":"10.1200\/JCO.2017.35.6_suppl.136"},{"key":"14_CR24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:149\u201358.","journal-title":"Lancet Oncol."},{"key":"14_CR25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.eururo.2015.09.013","volume":"69","author":"M Tucci","year":"2016","unstructured":"Tucci M, Bertaglia V, Vignani F, Buttigliero C, Fiori C, Porpiglia F, et al. Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69:563\u201373.","journal-title":"Eur Urol."},{"key":"14_CR26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/pcan.2016.10","volume":"19","author":"RE Miller","year":"2016","unstructured":"Miller RE, Sweeney CJ. Chemotherapy for metastatic castrate-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2016;19:139\u201344.","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"14_CR27","doi-asserted-by":"crossref","unstructured":"Tagawa STPE, Bruce JY, Lim EA, Petrylak DP, Peng W. Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2014;32:abs 5025 is an abstract (ASCO, Chicago IL).","DOI":"10.1200\/jco.2014.32.15_suppl.5025"},{"key":"14_CR28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.urology.2016.02.010","volume":"96","author":"M Santis De","year":"2016","unstructured":"De Santis M, Saad F. Practical guidance on the role of corticosteroids in the treatment of metastatic castration-resistant prostate cancer. Urology. 2016;96:156\u201364.","journal-title":"Urology."},{"key":"14_CR29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ajur.2016.11.005","volume":"4","author":"MMAJ Pollard","year":"2017","unstructured":"Pollard MM,AJ, Diefenbach MA, Hall SJ. Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer. Asian J Urol. 2017;4:37\u201343.","journal-title":"Asian J Urol."},{"key":"14_CR30","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S1470-2045(16)30227-3","volume":"17","author":"JW Hearn","year":"2016","unstructured":"Hearn JW, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang KH, et al. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol. 2016;17:1435\u201344.","journal-title":"Lancet Oncol."},{"key":"14_CR31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/pcan.2016.17","volume":"19","author":"ES Antonarakis","year":"2016","unstructured":"Antonarakis ES, Armstrong AJ, Dehm SM, Luo J. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis. 2016;19:231\u201341.","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"14_CR32","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028\u201338.","journal-title":"N Engl J Med."},{"key":"14_CR33","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms6548","volume":"5","author":"G Galletti","year":"2014","unstructured":"Galletti G, Matov A, Beltran H, Fontugne J, Miguel Mosquera J, Cheung C, et al. ERG induces taxane resistance in castration-resistant prostate cancer. Nat Commun. 2014;5:5548.","journal-title":"Nat Commun."}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-017-0014-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-017-0014-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-017-0014-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:32:55Z","timestamp":1684618375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-017-0014-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,20]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["14"],"URL":"https:\/\/doi.org\/10.1038\/s41391-017-0014-9","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"type":"print","value":"1365-7852"},{"type":"electronic","value":"1476-5608"}],"subject":[],"published":{"date-parts":[[2017,12,20]]}}}